Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

NK cell immunotherapy after analytic treatment interruption is associated with HIV viral control.

Molecular therapy. Advances·2026
Same author

T<sub>reg</sub> cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer.

Science immunology·2026
Same author

Multiplex engineering of rhesus macaque NK cells enhances homing to sites of HIV replication in B cell follicles.

bioRxiv : the preprint server for biology·2026
Same author

Analyzing cell migration history in vivo using fluorescent fibrillar collagen trails.

Communications biology·2026
Same author

CRISPRessoSea: streamlined analysis and comparison of pooled amplicon CRISPR screens.

BMC bioinformatics·2026
Same author

Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy.

Molecular therapy. Advances·2026

相关实验视频

Updated: Sep 11, 2025

A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments
12:21

A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments

Published on: August 6, 2013

10.7K

一个单一的基础编辑平台,用于免疫细胞的多功能多重体工程.

Joseph G Skeate1,2,3, Nicholas J Slipek1,2,3, Walker S Lahr1,2,3

  • 1Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

bioRxiv : the preprint server for biology
|August 12, 2025
PubMed
概括

这项研究引入了一种新的基编辑方法,用于设计更安全的仿真抗原受体 (CAR) T细胞. INSERT平台使得高效的,单步的CAR T细胞产生,具有增强的抗癌功能和最小的非目标效应.

更多相关视频

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

433
The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

16.1K

相关实验视频

Last Updated: Sep 11, 2025

A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments
12:21

A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments

Published on: August 6, 2013

10.7K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

433
The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

16.1K

科学领域:

  • 生物技术是生物技术.
  • 免疫治疗是一种免疫疗法.
  • 基因编辑 基因编辑

背景情况:

  • 目前的CAR T细胞工程方法由于随机集成或双链断裂而面临安全问题.
  • 开发更安全,更有效的CAR T细胞生成方法对于治疗应用至关重要.

研究的目的:

  • 开发一个全合一的多重基因淘汰和淘汰的工具,用于先进的CAR T细胞工程.
  • 利用基编辑器尼克酶活动来刺激同质导向修复以获得精确的CAR T细胞修饰.

主要方法:

  • 杆化细胞因子和腺因基编辑器 (ABE) 尼克酶活性以促进同质导向修复 (HDR).
  • 采用了新的sgRNA设计和rAAV传递的DNA模板,在人类T细胞中高效地进行ABE8e刺激的HDR.
  • 获得多重基因淘汰 (>95%的B2M/CD3ε/PDCD1/CISH的四重KO) 与CAR T细胞淘汰一起.

主要成果:

  • 已证明高功能现成CAR T细胞的高效单步生成,向CD19,CD33或美索林.
  • 没有观察到可检测的转移或显著的非目标编辑,这表明安全性很高.
  • 展示了对多个癌症细胞系和3D球形模型的有效性.

结论:

  • 同步工程重编程T细胞 (INSERT) 平台的代号为CAR T细胞工程提供了一种安全和简化的方法.
  • 这种方法可以创建具有增强功能和提高安全性的先进的CAR T细胞产品.
  • INSERT为开发下一代癌症免疫疗法建立了一个有前途的平台.